Dhinakar Kompala obtained his B. Tech. in Chemical Engineering from Indian Institute of Technology, Madras, India in 1979 and his M.S. and Ph.D. in Chemical Engineering from Purdue University, USA in 1982 and 1984 respectively. He served on the faculty of the Department of Chemical and Biological Engineering at the University of Colorado, Boulder since 1985. He was a recipient of Presidential Young Investigator award from National Science Foundation in 1988.

Dhinakar’s research expertise is in bioprocess engineering, recombinant mammalian and microbial cell cultures, bioreactor design and operating strategies, metabolic engineering, and modeling of biological growth and production processes. He trained over 30 graduate and postdoctoral researchers, most of whom have joined the biotechnology industry. He served on editorial boards of the Journal of Biotechnology, International Journal of Biological Sciences and as Section Editor of BMC Biotechnology.

Dhinakar was co-founder of a biotech startup company, Richcore Lifesciences Private Limited, in Bangalore, India in July 2008. He served as the Chief Scientific Officer, Director of R&D, and on the Board of Directors of this growing company until November 2012. Taking a phased early retirement from the University of Colorado in May 2014, Dhinakar is now devoting full time to his new biotech startup, Sudhin Biopharma Company in Superior, CO and its subsidiary R&D operations at Sudhin Biotech Private Limited in Chennai, India.

Sushila Kompala hails from Bangalore, India and completed her medical education at Bangalore Medical College. She completed her residency in Diagnostic Radiology at the University of Colorado Health Sciences Center and her fellowship in Body Imaging at Cedars Sinai Medical Center in Los Angeles, CA. She is a practicing radiologist, focusing on women’s health and mammography.

Dr. Utlaut has been practicing medicine for over 33 years. He is Board Certified in Internal Medicine and Ophthalmology, studied at the National Eye Institute, was a researcher at Moorfields Hospital, London, served on the faculty at Stanford University and, acted as Attending Physician to the Royal Family of Saudi Arabia. Dr. Utlaut held prior posts as President of the Colorado Business Coalition for Health, Director of the Royal Hospital at Taif, Saudi Arabia; and, on the Board of Directors for Magpie Healthcare and Avivid Business Solutions. Dr. Utlaut was Valedictorian in Mathematics at the University of Colorado, and holds a M.D. from Johns Hopkins School of Medicine.

Robert Sclafani, is Professor and Director of Cancer Cell Biology and Molecular Biology Programs at the University of Colorado School of Medicine. He received his B.A. in 1975 and Ph.D. in 1981 in Molecular Biology from Columbia University. He did postdoctoral research at the University of Washington in Seattle from 1981-1984 before joining the faculty at Colorado in 1985. His research focuses on yeast biotechnology and molecular genetics and cancer chemoprevention. He has published over 65 peer-reviewed articles in scientific journals and has been awarded grants from NIH, DOD, NSF and several private foundations. He sits on the editorial board of the journal, “G3:Genes, Genomes and Genetics”, has reviewed grants for both US and EU agencies and is on the Scientific Advisory Committee for the International Cancer Research Symposia in India. In 2011, he was elected a fellow of the American Academy of Microbiology.

Robert Scheinman received his PhD in Pharmacology at the University of WA in Seattle. He then did Postdoctoral training with Albert Baldwin at UNC at Chapel Hill, NC. During his postdoc, he studied the biology of the transcription factor; NF-kB which began his long interest in the regulation of inflammation and its contribution to human disease. Upon receiving a faculty position at the University of Colorado School of Pharmacy, he began performing studies on diseases with a strong inflammatory component such as Diabetes and Rheumatoid Arthritis. He has made contributions to the understanding of the antiinflammatory mechanism of glucocorticoids, T cell function in inflammatory and autoimmune disease, and most recently, in the development of new therapeutics to treat Rheumatoid Arthritis and Diabetic complications such as retinopathy. He teaches extensively in both Pharmacy programs as well as Graduate Programs in Toxicology and Pharmaceutical Sciences.

Satish Garg is Professor of Medicine and Pediatrics at the Young Adult Clinic of the Barbara Davis Center for Diabetes of the University Of Colorado School Of Medicine in Denver, Colorado. Dr. Garg is the Editor in-chief of Diabetes Technology and Therapeutics Journal and Chair of the planning committee for Clinical Therapeutics and New Technology area for 2007 and 2008 Annual American Diabetes Associations meetings. He is a member of the many Endocrine and Diabetes Societies such as: International Diabetes Federation, the American Diabetes Association, the Endocrine Society of India, and the European Association of Study for Diabetes, the Regional Pediatric Endocrine Society of Colorado, the Research Society for Study of Diabetes Mellitus, and numerous other professional societies in both the United States and India. He is an international lecturer and speaker, and has published many chapters in the books, on the editorial boards for many of the diabetes journals globally and has published more than 230 original manuscripts in peer-review journals.

John is President of Scientific Bioprocessing and Chairman of the Board of our parent, Scientific Industries (SCND-OTCQX). He is a magnificent amateur — sometimes the emphasis on amateur and sometimes magnificent. His 2002 acquisition of interests in sixteen drug delivery businesses from Elan Pharmaceuticals really sparked his interest in life sciences.

He is an avid student of science and art. He is a blogger on how art can amplify science education at www.theageofwonder.com . He recently participated in the citizen scientist American Gut Project. John is a graduate of Rutgers University and earned a History degree. He loves to play cards and beat his girlfriend at Gin.

Scott Rudge is a founding member of RMC Pharmaceutical Solutions, and currently serves as its technical leader. Scott brings 20 years of experience in the pharmaceutical industry, and an additional seven years of academic and government sponsored research and development in bioprocessing to the RMC Pharmaceutical Solutions team. Scott received his PhD in chemical engineering from Purdue University in 1989. He is an adjunct professor of chemical engineering at the University of Colorado, a guest researcher at the National Institute of Standards and Technology, and co-author of a leading text book on bioseparations. Scott has also worked at FeRx Incorporated, Amylin Pharmaceuticals Incorporated, Synergen Incorporated, and the National Institute of Standards and Technology. In addition to his role as chief technical officer, Scott assists clients as a Principal Consultant.

Peter Brown received his BA, MS and Ph.D. in various areas of cell and molecular biology (Middlebury College, San Diego State, Oak Ridge National Laboratory and the University of Tennessee). After a post-doctoral fellowship at Stanford studying mechanisms of gene amplification, Peter shifted focus to mammalian cell process development at BioResponse, Chiron, Aviron and Avigen. After consulting for many years in scale-up and optimization of mammalian cell cultures for the production of biologics, he commercialized a series of multi-lamellar cell settlers through his company Biotechnology Solutions.

Khishore Pridhivi obtained his Bachelor of Science degree in Visual Communication from Sathyabama University, Chennai. He pursued his higher studies in Entertainment Business Management from Vancouver Film School, Canada. On returning to Chennai, he completed his MBA in finance and marketing. He now actively runs his family's export business in the field of handlooms and textiles. Khishore serves on the board of directors of the majority-owned subsidiary in India, Sudhin Biotech Private Limited.

Premsingh Samuel obtained his B. Tech in Chemical Engineering from University of Madras in 2001 and Ph. D in Biotechnology from Centre for Biotechnology, Anna University, Chennai, India in 2009. He was a visiting scholar at Anschutz Medical Campus, University of Colorado in 2014. He has 15 years of research experience in heterologous expression of proteins in yeast Pichia pastoris expression system as well as bacterial expression systems. Post Ph. D, he joined a start up Biotech Company in Bangalore, India, and was instrumental in establishment of R & D, production facility and product commercialization. He has eleven years of industrial experience with expertise in the area of genetic engineering, bioprocess development, technology transfer and scale up studies.

Sudhin Biopharma’s Director of Device Design and Fabrication Braden Smith is holding the first generation BioSettler150 (3.8 liter) and the second generation BioSettler75 (1000 ml), both made of polypropylene.

Sudhin’s Founder & CEO Dhinakar Kompala is holding polycarbonate versions of the second generation BioSettler75 (250 and 2000 ml).

Sudhin Biopharma’s principal scientist Christopher Glascock is carrying a larger scale model of the second generation BioSettler300 (20 liters).

On the floor rests a BioSettler300-24 liters stainless steel steam-sterlizable BioSettler.

Team of Sudhin Biotech scientists standing on the grounds of the Center for Food Technology at Anna University, Chennai, India

From Left to Right:

Susipriya Thangaraj, Analytical Chemist

Suresh Krishnan, Bioprocess Engineering, Upstream

Khishore Pridhivi, Director of Operations

Vimal Ponnusamy, Bioprocess Engineering, Downstream

Premsingh Samuel, Ph.D. Director, R&D

Kamatchi Kavitha, Ph.D. Senior Scientist

Dhinakar Kompala, Founder & CEO